logo

Biohaven Pharmaceutical Holding Co Ltd. (BHVN)



Trade BHVN now with
  Date
  Headline
2/10/2020 7:28:00 AM Biohaven Reports Negative Topline Results From Phase 3 Clinical Trial On Troriluzole Compared To Placebo
2/6/2020 7:45:47 AM Kleo Pharma Gets IND Authorization To Proceed From FDA For Multiple Myeloma Therapeutic
1/29/2020 7:39:54 AM Biohaven Announces Pricing Of Public Offering Of 4.83 Mln Shares At $51.75/Shr
1/28/2020 5:34:52 PM Biohaven Pharmaceutical Begins Public Offering Of $250 Mln Of Its Common Shares
12/17/2019 7:34:06 AM Biohaven Announces Positive Topline Results In Pivotal Phase 2/3 Study Of Vazegepant
10/28/2019 7:32:56 AM Biohaven Completes Enrollment In Phase 3 Generalized Anxiety Disorder Trial Of Troriluzole
9/10/2019 7:31:36 AM Biohaven Announces Completion Of Enrollment Of Pivotal Phase 2/3 Trial Of Vazegepant
8/7/2019 7:44:37 AM Biohaven Completes Enrollment In Pivotal Phase 3 Preventive Treatment Of Migraine Trial
7/22/2019 7:34:50 AM Biohaven Says Enrollment In T2 Protect AD Study Is Progressing On Timelines
7/15/2019 7:33:08 AM Biohaven Publishes Positive Phase 3 Trial Of Rimegepant Zydis For Acute Treatment Of Migraine In The Lancet
7/1/2019 7:31:56 AM Biohaven Enrolls First Patient In Phase 2 Clinical Trial Of Rimegepant, Oral CGRP Receptor Antagonist
6/24/2019 7:31:43 AM Biohaven To Present 16 Abstracts At 2019 American Headache Society AHS Highlighting New Data With Rimegepant
6/18/2019 10:13:47 PM Biohaven Pharmaceutical Announces Pricing Of Underwritten Public Offering Of 6.98 Mln Shares At $43.00/shr